The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age

The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age

Fragility scales are intended to help in therapeutic decisions. Here, we asked if the fragility assessment in MM patients ≥ 75 years old qualified for treatment by the local physician correlates with the choice of treatment: a two- or three-drug regimens. Between 7/2018 and 12/2019, we prospectively...

Full description

Bibliographic Details
Main Authors: Agata Tyczyńska, Marcela Krzysława Krzempek, Alexander Jorge Cortez, Artur Jurczyszyn, Katarzyna Godlewska, Hanna Ciepłuch, Edyta Subocz, Janusz Hałka, Anna Kulikowska de Nałęcz, Anna Wiśniewska, Alina Świderska, Anna Waszczuk-Gajda, Joanna Drozd-Sokołowska, Renata Guzicka-Kazimierczak, Kamil Wiśniewski, Agnieszka Porowska, Wanda Knopińska-Posłuszny, Janusz Kłoczko, Piotr Rzepecki, Dariusz Woszczyk, Hanna Symonowicz, Grzegorz Władysław Basak, Barbara Zdziarska, Krzysztof Jamroziak, Jan M. Zaucha
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Cancers
Subjects:
frailty
elderly
multiple myeloma
choice of treatment
over 75 years old
early mortality
Online Access:https://www.mdpi.com/2072-6694/15/13/3469

Internet

https://www.mdpi.com/2072-6694/15/13/3469

Similar Items